Overview
The purpose of this study is to learn about:
- effects of living with COVID-19 and
- how effective is nirmatrelvir-ritonavir in treating COVID-19.
This is a study of two groups of COVID-19 patients in Taiwan.
In Group 1 the below participants were included in the study:
- Patients of all ages.
- Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021.
- Cases of patients registered in the databases.
In Group 2 the below participants were included in the study:
- Participants who are 12 years or older.
- Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.
Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.
The study will look at:
- the nature of Covid-19 disease.
- as well as the experiences of people receiving the nirmatrelvir-ritonavir.
This study will help to:
- understand what type of patients will need to be admitted to hospitals.
- see severe results due to COVID 19 infection.
- have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Eligibility
Cohort 1:
Inclusion Criteria:
- Patients of all ages
- Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
- Cases of patients registered in the databases
Exclusion Criteria:
- Patients without COVID-19 diagnosis
Cohort 2:
Inclusion Criteria:
- ≥12 years of age
- Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
Exclusion Criteria:
- Patients without COVID-19 diagnosis